Science Corporation, founded by ex-Neuralink president Max Hodak, is preparing to place a 520-electrode cortical surface sensor on a human brain during an already-scheduled surgery. Yale neurosurgery chair Murat Günel will lead the clinical programme, with trials potentially beginning in 2027. Unlike Neuralink's penetrating implants, the device rests on the cortex surface and is designed to eventually incorporate lab-grown, light-sensitive neurons — a biohybrid approach that distinguishes Science Corp from all competitors. The first placement will be recording-only, bypassing FDA approval via institutional review boards. The company also has PRIMA, a retinal implant that restored vision in 38 patients (published in NEJM), with CE mark approval expected mid-2026. Science Corp recently closed a $230M Series C at a $1.5B valuation, bringing total funding to $490M.
Sort: